Genetics & Stem Cells News

Medindia's Press Release’ section provides the latest press release on Genetics & Stem Cells from across the world for the global audience. This page links to 1961 Genetics & Stem Cells press releases.

Study Shows two-thirds of the Population Is Hypnotizable

PR Newswire SAN FRANCISCO, March 20, 2025 Study Shows two-thirds of the Population Is Hypnotizable—Recent Genetic Findings Reveal Why SAN FRANCISCO, March 20, 2025 /PRNewswire/ -- Reveri, the world-leading self-hypnosis app co-founded by ...

Skyhawk Therapeutics Presents at Huntington's Disease Youth Organization HDYO International Congress 2025

PR Newswire BOSTON, March 15, 2025 Skyhawk presents today on its novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's Disease to members of the Huntington's Disease Youth Organization, at the annual HYDO International ...

SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

PR Newswire BARCELONA, Spain, March 13, 2025 BARCELONA, Spain, March 13, 2025 /PRNewswire/ -- SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today ...

The Role of CRISPR Libraries in Advancing Cancer Research: From Target Identification to Personalized Therapy

CRISPR-Cas9 technology has revolutionized genetic research, providing an efficient method for gene editing. CRISPR libraries , collections of guide RNAs (gRNAs) designed for large-scale genetic screens, have emerged as powerful tools in cancer ...

RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation

PR Newswire PRINCETON, N.J., March 9, 2025 PRINCETON, N.J., March 9, 2025 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA ...

Sucraid® (sacrosidase) Oral Solution. Free 4-Day Trial Now Available. The only FDA- approved therapy to treat CSID (Congenital Sucrase-Isomaltase Deficiency)

PR Newswire VERO BEACH, Fla., March 1, 2025 VERO BEACH, Fla., March 1, 2025 /PRNewswire/ -- QOL Medical, LLC, a ground-breaking rare disease pharmaceutical company, has announced Sucraid® (sacrosidase) Oral Solution has been shown to be 81% ...

Avirmax Biopharma Initiates IND-enabling Studies of ABI-201; a Breakthrough Gene Therapy for Dry Age-related Macular Degeneration

PR Newswire HAYWARD, Calif., Feb. 28, 2025 HAYWARD, Calif., Feb. 28, 2025 /PRNewswire/ -- Avirmax Biopharma, Inc., a leader in developing the next generation of AAV gene therapies, today announced the commencement of Investigational New Drug ...

Apertura Gene Therapy Supports the Broad Institute in Development of Gene Therapy for Prion Disease Using Engineered AAV Capsid Targeting TfR1 for CNS Delivery

PR Newswire BOSTON and NEW YORK, Feb. 28, 2025 BOSTON and NEW YORK, Feb. 28, 2025 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions, supports the Broad Institute of MIT and Harvard, ...

ERS Genomics: European Patent Office Grants CVC Portfolio Key CRISPR Patent

PR Newswire DUBLIN and CHESTER, England, Feb. 26, 2025 European Patent Office grants new CRISPR/Cas9 patent (EP 4 289 948) to CVC, with broad claims covering guide RNAs and their combination with Cas9. Patent strengthens CVC's leading ...

YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)

PR Newswire SHANGHAI, Feb. 25, 2025 SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines, today reported ...

First Prev
1
2
3
4
5
6
7
8
9
10
Next
Last